Artikel: Romidepsin and tamoxifen cooperatively induce senescence of pancreatic cancer cells through downregulation of FOXM1 expression and induction of reactive oxygen species/lipid peroxidation
Molecular biology reports. 2022 May, v. 49, no. 5
2022
Abstract: BACKGROUND: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority. ... ...
| Abstract | BACKGROUND: Although improvement has been made in therapeutic strategies against pancreatic carcinoma, overall survival has not significantly enhanced over the past decade. Thus, the establishment of better therapeutic regimens remains a high priority. METHODS: Pancreatic cancer cell lines were incubated with romidepsin, an inhibitor of histone deacetylase, and tamoxifen, and their effects on cell growth, signaling and gene expression were analyzed. Xenografts of human pancreatic cancer CFPAC1 cells were medicated with romidepsin and tamoxifen to evaluate their effects on tumor growth. RESULTS: The inhibition of the growth of pancreatic cancer cells induced by romidepsin and tamoxifen was effectively reduced by N-acetyl cysteine and α-tocopherol, respectively. The combined treatment greatly induced reactive oxygen species production and mitochondrial lipid peroxidation, and these effects were prevented by N-acetyl cysteine and α-tocopherol. Tamoxifen enhanced romidepsin-induced cell senescence. FOXM1 expression was markedly downregulated in pancreatic cancer cells treated with romidepsin, and tamoxifen further reduced FOXM1 expression in cells treated with romidepsin. Siomycin A, an inhibitor of FOXM1, induced senescence in pancreatic cancer cells. Similar results were obtained in knockdown of FOXM1 expression by siRNA. CONCLUSION: Since FOXM1 is used as a prognostic marker and therapeutic target for pancreatic cancer, a combination of the clinically available drugs romidepsin and tamoxifen might be considered for the treatment of patients with pancreatic cancer. |
|---|---|
| Schlagwörter | alpha-tocopherol ; carcinoma ; cell growth ; cell senescence ; cysteine ; gene expression ; histone deacetylase ; humans ; lipid peroxidation ; mitochondria ; molecular biology ; neoplasm cells ; pancreatic neoplasms ; reactive oxygen species ; tamoxifen ; xenotransplantation |
| Sprache | Englisch |
| Erscheinungsverlauf | 2022-05 |
| Umfang | p. 3519-3529. |
| Erscheinungsort | Springer Netherlands |
| Dokumenttyp | Artikel |
| ZDB-ID | 186544-4 |
| ISSN | 1573-4978 ; 0301-4851 |
| ISSN (online) | 1573-4978 |
| ISSN | 0301-4851 |
| DOI | 10.1007/s11033-022-07192-9 |
| Datenquelle | NAL Katalog (AGRICOLA) |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Bonn
| Z 78/728: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.
Fernleihe an ZB MED
Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.